NeuroSense Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for NeuroSense Therapeutics (NRSN).

Price Target Range — 6 Quarters

Analyst Consensus — 4 Analysts

3Buy

1Hold

Consensus RatingBuy# Analysts4Avg. Consensus PT$131Upside to Avg. PT+3431.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 28, 2026	HC Wainwright & Co.	Lander Egaña Gorroño	PT Raise	Buy	$8→$52
Sep 3, 2026	HC Wainwright & Co.	Lander Egaña Gorroño	Initiate	Buy	$8
Apr 8, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Mar 25, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Mar 17, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Mar 10, 2026	Roth Capital	Boobalan Pachaiyappan	Initiate	Buy	$3
Mar 9, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Dec 22, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Nov 24, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Aug 15, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
Jul 10, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
May 12, 2025	D. Boral Capital	Jason Kolbert	Initiate	Buy	$14
Dec 16, 2024	Maxim Group	Naz Rahman	Downgrade	Buy→Hold	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52

HC Wainwright & Co. analyst Lander Egaña Gorroño maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and raises the price target from $8 to $52.

Benzinga Newsdesk

This SpaceX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts initiated coverage with Buy ratings on SpaceX, Securitize ; Overweight on Londian Wason.

Avi Kapoor

This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts initiated coverage: Neutral COP; Buy TLSA ($7), OXY ($73), NRSN ($8); Sell SM ($35).

Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $8

HC Wainwright & Co. analyst Lander Egaña Gorroño initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $8.

Benzinga Newsdesk

This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $175 price target and CROX has a Neutral rating.

Avi Kapoor

PRO
Roth Capital Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $3

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $3.

Benzinga Newsdesk

NeuroSense Therapeutics Ltd

뉴스

파트너 / 기고자

벤징가 글로벌

NeuroSense Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52

This SpaceX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRO
HC Wainwright & Co. Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $8

This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRO
Roth Capital Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $3

People Also Watch

People Also Watch

NeuroSense Therapeutics Ltd

뉴스

파트너 / 기고자

벤징가 글로벌

NeuroSense Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52

This SpaceX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PROHC Wainwright & Co. Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $8

This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRORoth Capital Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $3

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on NeuroSense Therapeutics, Raises Price Target to $52

PRO
HC Wainwright & Co. Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $8

PRO
Roth Capital Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $3